



## **CERTIFICATE OF ANALYSIS No.: 2023-12958**

## CLIENT

KANNABIO HEMP HELLAS, SKOUFA 110 38334 VOLOS, Greece

## SAMPLE \*

LIBIDON



. . .



. . . .

. . . . . . .

Sample condition: SUITABLE 2023-107712 Sample received: 19/09/2023 Work order: 2338037 Start of analysis: 22/09/2023 Sample ID: Analysis ID: 2023 315 PHL RPC 16C Sample type: Viscous liquid Method ID: End of analysis: 26/09/2023 Batch No.: \* K218D Method SOP: MET-LAB-001-08 Analyst: Domen Lavriha \* Information provided by the client.

. . . . . . .

~

CANNA	BINOID PROFILE	Concentration [% w/w]	uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	< LOQ	n/a	
CBDA	- Cannabidiolic acid	< LOQ	n/a	
CBGA	- Cannabigerolic acid	< LOQ	n/a	
CBG	- Cannabigerol	< LOQ	n/a	
CBD	- Cannabidiol	4.96	0.25	
THCV	- Tetrahydrocannabivarin	< LOQ	n/a	
CBN	- Cannabinol	2.58	0.13	
Δ <sup>9</sup> -THC	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
∆ <sup>8</sup> -THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
CBC	- Cannabichromene	< LOQ	n/a	
Δ <sup>9</sup> -THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
CBV	- Cannabivarin	< LOQ	n/a	
CBCA	- Cannabichromenic acid	< LOQ	n/a	
СВТ	- Cannabicitran	< LOQ	n/a	
CBE	- Cannabielsoin	< LOQ #	n/a	

Expanded

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

26/09/2023

End of Certificate

Approved by:

mag. Janja Ahej Analytical Laboratory Manager

Authorized by:

1 Tat

dr. Boštjan Jančar Chief Technology Officer